Correlation between lymphocyte responsiveness to mitogens and results of chemo-immunotherapy in patients with advanced cancer.

The effect of chemo-immunotherapy on lymphocyte responsiveness to phytohemagglutinin (PHA) and pokeweed mitogen (PWM) was investigated in patients with advanced cancer. Patients received OK-432, a streptococcal preparation, intratumorally and additional systemic MFC (mitomycin-C, 5-fluorouracil, and cytosine arabinoside) chemotherapy intravenously. Patients with high lymphocyte responsiveness to mitogens at the beginning of treatment were more responsive to chemo-immunotherapy than those with low responsiveness. Furthermore, lymphocyte responsiveness to PHA was maintained at a high level throughout the treatment. In contrast, patients with initially depressed lymphocyte responsiveness maintained low responsiveness throughout the treatment. A significant increase of inhibitory activity of the serum was observed in patients with poor results of treatment. From these results, it seems reasonable to conclude that the response to chemo-immunotherapy might be predicted by in-vitro lymphocyte responsiveness.